Peddock Capital Advisors buys $318,098 stake in Biogen Inc (BIIB)

Biogen Inc (BIIB) : Peddock Capital Advisors scooped up 161 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 1,095 shares of Biogen Inc which is valued at $318,098.Biogen Inc makes up approximately 0.21% of Peddock Capital Advisors’s portfolio.

Other Hedge Funds, Including , Msi Financial Services Inc reduced its stake in BIIB by selling 161 shares or 4.98% in the most recent quarter. The Hedge Fund company now holds 3,075 shares of BIIB which is valued at $905,311. Biogen Inc makes up approx 0.03% of Msi Financial Services Inc’s portfolio.Profit Investment Management reduced its stake in BIIB by selling 300 shares or 19.57% in the most recent quarter. The Hedge Fund company now holds 1,233 shares of BIIB which is valued at $363,008. Biogen Inc makes up approx 0.37% of Profit Investment Management’s portfolio. Daiwa Sb Investments Ltd. sold out all of its stake in BIIB during the most recent quarter. The investment firm sold 1,040 shares of BIIB which is valued $310,232.Bnp Paribas Arbitrage Sa boosted its stake in BIIB in the latest quarter, The investment management firm added 33,875 additional shares and now holds a total of 152,259 shares of Biogen Inc which is valued at $47,154,612. Biogen Inc makes up approx 0.19% of Bnp Paribas Arbitrage Sa’s portfolio.

Biogen Inc closed down -3.91 points or -1.33% at $290.5 with 11,49,803 shares getting traded on Friday. Post opening the session at $295.63, the shares hit an intraday low of $290.13 and an intraday high of $297.34 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.

Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Downgraded by Jefferies to ” Hold” on Sep 6, 2016.

Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.

Leave a Reply

Biogen Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Biogen Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.